53 results
Page 2 of 3
8-K
EX-1.1
1muiwqbjfo8f
17 Nov 21
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9:04am
424B5
oxabiaf7
17 Nov 21
Prospectus supplement for primary offering
9:02am
424B5
fbv90jlrwe518f8y3
15 Nov 21
Prospectus supplement for primary offering
5:24pm
8-K
EX-99.1
4o7l0878a1 624eqm
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
yfdk9e9
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
EX-1.1
pv5xkd018cv
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm
POS AM
EX-1.2
5gspix s7
4 Oct 19
Prospectus update (post-effective amendment)
4:59pm